TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07477587: A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Tra

Sponsor: Shanghai Henlius Biotech · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 258 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT07477587 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07477587 Rescue Dossier →